Mortality Due to COVID-19 in the COVID-AGEBRU Study

The COVID-Age Brugmann study aims to identify the clinical predictors of mortality risk in older patients admitted to an acute care unit due to COVID-19

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Covid19 COVID-19 Coronaviridae Infections Coronavirus Infections Frailty Infections Lung Diseases Morbidity, Multiple Nidovirales Infections Old Age; Debility Pathologic Processes Pathological Conditions, Signs and Symptoms Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

70 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Brugmann

Brussels, 1020, Belgium

About this study

The COVID-19 disease has been shown to be associated to higher mortality risk and health adverse consequences. Despite of the fact that the SAR-COV2 virus has been shown that affects every populations, the negative impact is higher in older people, pointing this population as the most severely affected.

The COVID-Age Brugmann study aims to identify if comorbidity, geriatric syndromes, and health issues at admission are associated to mortality risk in older patients admitted to an acute care unit due to COVID-19

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients aged 70 and older
Patients admitted to an acute care geriatric unit due to COVID-19
Patients with COVID-19 by PCR, serology or CT scan suggestive of this disease

Exclusion criteria

No other demographic or clinical exclusion criteria will be applied

Treatment and study plan

Primary outcomes

All-cause mortality during hospital admission (admission up to discharge time)

Time frame: Through study completion, an average of one month.

Vital status was obtained from medical records

Secondary outcomes

Prevalence of medical diseases and geriatric syndromes

Time frame: Through study completion, an average of one month.

Clinical and demographical conditions, and geriatric syndromes

Sponsors and collaborators

Lead sponsor

Brugmann University Hospital

Other

Registry information

Official study title

Predictors of Intrahospital Mortality in Older Patients Admitted Due to COVID-19 in the COVID-19 AGEBRU Study

Acronym: COVID-AGEBRU

Important dates

Study start: 2020
Primary completion: 2020
Study completion: 2020
First posted: Feb 16, 2021
Registry last updated: Apr 6, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed